Literature DB >> 27253694

Cancer treatment and survivorship statistics, 2016.

Kimberly D Miller1, Rebecca L Siegel2, Chun Chieh Lin3, Angela B Mariotto4, Joan L Kramer5, Julia H Rowland6, Kevin D Stein7, Rick Alteri8, Ahmedin Jemal9.   

Abstract

The number of cancer survivors continues to increase because of both advances in early detection and treatment and the aging and growth of the population. For the public health community to better serve these survivors, the American Cancer Society and the National Cancer Institute collaborate to estimate the number of current and future cancer survivors using data from the Surveillance, Epidemiology, and End Results cancer registries. In addition, current treatment patterns for the most prevalent cancer types are presented based on information in the National Cancer Data Base and treatment-related side effects are briefly described. More than 15.5 million Americans with a history of cancer were alive on January 1, 2016, and this number is projected to reach more than 20 million by January 1, 2026. The 3 most prevalent cancers are prostate (3,306,760), colon and rectum (724,690), and melanoma (614,460) among males and breast (3,560,570), uterine corpus (757,190), and colon and rectum (727,350) among females. More than one-half (56%) of survivors were diagnosed within the past 10 years, and almost one-half (47%) are aged 70 years or older. People with a history of cancer have unique medical and psychosocial needs that require proactive assessment and management by primary care providers. Although there are a growing number of tools that can assist patients, caregivers, and clinicians in navigating the various phases of cancer survivorship, further evidence-based resources are needed to optimize care. CA Cancer J Clin 2016;66:271-289.
© 2016 American Cancer Society. © 2016 American Cancer Society, Inc.

Entities:  

Keywords:  prevalence; statistics; survivorship; treatment patterns

Mesh:

Year:  2016        PMID: 27253694     DOI: 10.3322/caac.21349

Source DB:  PubMed          Journal:  CA Cancer J Clin        ISSN: 0007-9235            Impact factor:   508.702


  1703 in total

1.  Low expression of miR-let-7a promotes cell growth and invasion through the regulation of c-Myc in oral squamous cell carcinoma.

Authors:  Chunyang Luo; Jiyong Zhang; Yi Zhang; Xiao Zhang; Yinan Chen; Weimin Fan
Journal:  Cell Cycle       Date:  2020-06-28       Impact factor: 4.534

Review 2.  The Intensive Care Medicine research agenda on critically ill oncology and hematology patients.

Authors:  Elie Azoulay; Peter Schellongowski; Michael Darmon; Philippe R Bauer; Dominique Benoit; Pieter Depuydt; Jigeeshu V Divatia; Virginie Lemiale; Maarten van Vliet; Anne-Pascale Meert; Djamel Mokart; Stephen M Pastores; Anders Perner; Frédéric Pène; Peter Pickkers; Kathryn A Puxty; Francois Vincent; Jorge Salluh; Ayman O Soubani; Massimo Antonelli; Thomas Staudinger; Michael von Bergwelt-Baildon; Marcio Soares
Journal:  Intensive Care Med       Date:  2017-07-19       Impact factor: 17.440

Review 3.  Rapid Fire: Infectious Disease Emergencies in Patients with Cancer.

Authors:  Stephanie Charshafian; Stephen Y Liang
Journal:  Emerg Med Clin North Am       Date:  2018-06-11       Impact factor: 2.264

4.  A comparison of general, genitourinary, bowel, and sexual quality of life among long term survivors of prostate, bladder, colorectal, and lung cancer.

Authors:  Scott D Ramsey; Ingrid J Hall; Judith Lee Smith; Donatus U Ekwueme; Catherine R Fedorenko; Karma Kreizenbeck; Aasthaa Bansal; Ian M Thompson; David F Penson
Journal:  J Geriatr Oncol       Date:  2020-07-29       Impact factor: 3.599

5.  Pax-5 Inhibits NF-κB Activity in Breast Cancer Cells Through IKKε and miRNA-155 Effectors.

Authors:  Jason Harquail; Nicolas LeBlanc; Carine Landry; Nicolas Crapoulet; Gilles A Robichaud
Journal:  J Mammary Gland Biol Neoplasia       Date:  2018-07-21       Impact factor: 2.673

6.  Significant expression of CHK1 and p53 in bladder urothelial carcinoma as potential therapeutic targets and prognosis.

Authors:  Linfeng Zheng; Yuping Zhu; Lei Lei; Wenyong Sun; Guoping Cheng; Shifeng Yang
Journal:  Oncol Lett       Date:  2017-11-03       Impact factor: 2.967

7.  Ovarian tissue cryopreservation (OTC) in prepubertal girls and young women: an analysis of parents' and patients' decision-making.

Authors:  Chantae S Sullivan-Pyke; Claire A Carlson; Maureen Prewitt; Clarisa R Gracia; Jill P Ginsberg
Journal:  J Assist Reprod Genet       Date:  2018-02-01       Impact factor: 3.412

8.  Complete Response to Single-agent Palbociclib in Metastatic Breast Cancer: A Case Report.

Authors:  Sri Lakshmi Hyndavi Yeruva; Mehrbod Som Javadi; Vered Stearns
Journal:  Clin Breast Cancer       Date:  2017-12-21       Impact factor: 3.225

9.  Lovastatin protects against cisplatin-induced hearing loss in mice.

Authors:  Katharine Fernandez; Katie K Spielbauer; Aaron Rusheen; Lizhen Wang; Tiffany G Baker; Stephen Eyles; Lisa L Cunningham
Journal:  Hear Res       Date:  2020-02-06       Impact factor: 3.208

10.  miR-1204 targets VDR to promotes epithelial-mesenchymal transition and metastasis in breast cancer.

Authors:  Xiaoyan Liu; Lei Bi; Qin Wang; Mingxin Wen; Ce Li; Yidan Ren; Qinlian Jiao; Jian-Hua Mao; Chuanxin Wang; Guangwei Wei; Yunshan Wang
Journal:  Oncogene       Date:  2018-03-20       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.